Table 1. Principal clinical,... | American Society of Hematology

Table 1.

Principal clinical, morphological and immunohistochemical data of 45 patients with transformed mycosis fungoides (T-MF)

Patient, Sex (M/F), Age (y)	Interval from Diagnosis of MF to T-MF (y)	Stage at T-MF	% of Large Cells at T-MF^*	Expression of CD30 at T-MF^†	Survival After T-MF (mo)	Extracutaneous Involvement	Patient Status^‡
1. M, 74	0	IVA (T2)	3	0	36	yes	D
2. M, 83	0	IIB (T3)	2	0	30	no	D
3. M, 49	3	IIB (T3)	3	0	57	no	A
4. F, 73	2	IIB (T3)	3	0	48	no	D
5. F, 78	8	IVA (T3)	2	0	48	yes	D
6. F, 70	2	IIB (T3)	2	1	48	no	D
7. F, 87	7	IIB (T3)	3	2	12	no	D
8. F, 69	9	IIB (T3)	3	2	33	no	A
9. F, 36	32	IIB (T3)	2	2	105	no	A
10. F, 77	18	IB (T2)	1	0	L	L	L
11. M, 50	10	IVA (T3)	2	0	31	yes	A
12. M, 64	15	IIB (T3)	3	0	12	yes	D
13. F, 75	6	IIB (T3)	1	1	24	no	A
14. F, 47	11	IIB (T3)	3	0	31	no	A
15. M, 40	0	IVA (T2)	2	1	7	yes	D
16. F, 72	7	IVA (T3)	2	0	12	yes	D
17. M, 40	5	IVA (T3)	3	0	33	yes	D
18. M, 76	7	IVA (T3)	1	0	10	yes	A
19. M, 61	2	IVA (T3)	3	0	30	yes	D
20. M, 57	3	IVA (T3)	1	0	15	yes	D
21. M, 79	2	IIB (T3)	3	0	15	no	D
22. M, 67	15	IVA (T3)	2	0	25	yes	A
23. M, 90	5	IIB (T3)	3	2	15	no	D
24. M, 85	4	IVA (T3)	3	0	4	yes	D
25. M, 31	8	IVA (T3)	3	1	71	yes	A
26. F, 81	2	IIB (T3)	3	1	18	no	A
27. F, 68	4	IB (T2)	2	0	35	no	A
28. M, 75	1	IIB (T3)	2	0	12	yes	D
29. M, 67	1	IVA (T3)	3	0	10	yes	A
30. M, 56	1	IIB (T3)	1	0	18	no	A
31. F, 72	7	IVA (T3)	2	0	12	yes	D
32. F, 81	2	IVA (T2)	2	0	3	yes	D
33. M, 69	11	IVA (T3)	3	0	8	yes	D
34. M, 80	16	IIB (T3)	3	0	5	no	D
35. M, 45	4	IIB (T3)	2	0	36	yes	D
36. F, 43	3	IIB (T3)	3	0	96	no	A
37. F, 75	32	IIB (T3)	3	2	144	no	A
38. F, 82	11	IIB (T3)	2	1	60	no	D
39. F, 72	10	IIB (T3)	2	2	38	no	D
40. M, 43	0	III (T3)	2	0	22	yes	D
41. M, 71	0	IIB (T3)	2	0	36	no	A
42. M, 50	0	IVA (T3)	1	0	4	no	D
43. M, 37	0	IVA (T3)	2	1	16	no	A
44. F, 75	15	IIB (T3)	1	0	1	no	D
45. M, 62	10	IIB (T3)	2	2	3	no	A

Patient, Sex (M/F), Age (y)	Interval from Diagnosis of MF to T-MF (y)	Stage at T-MF	% of Large Cells at T-MF^*	Expression of CD30 at T-MF^†	Survival After T-MF (mo)	Extracutaneous Involvement	Patient Status^‡
1. M, 74	0	IVA (T2)	3	0	36	yes	D
2. M, 83	0	IIB (T3)	2	0	30	no	D
3. M, 49	3	IIB (T3)	3	0	57	no	A
4. F, 73	2	IIB (T3)	3	0	48	no	D
5. F, 78	8	IVA (T3)	2	0	48	yes	D
6. F, 70	2	IIB (T3)	2	1	48	no	D
7. F, 87	7	IIB (T3)	3	2	12	no	D
8. F, 69	9	IIB (T3)	3	2	33	no	A
9. F, 36	32	IIB (T3)	2	2	105	no	A
10. F, 77	18	IB (T2)	1	0	L	L	L
11. M, 50	10	IVA (T3)	2	0	31	yes	A
12. M, 64	15	IIB (T3)	3	0	12	yes	D
13. F, 75	6	IIB (T3)	1	1	24	no	A
14. F, 47	11	IIB (T3)	3	0	31	no	A
15. M, 40	0	IVA (T2)	2	1	7	yes	D
16. F, 72	7	IVA (T3)	2	0	12	yes	D
17. M, 40	5	IVA (T3)	3	0	33	yes	D
18. M, 76	7	IVA (T3)	1	0	10	yes	A
19. M, 61	2	IVA (T3)	3	0	30	yes	D
20. M, 57	3	IVA (T3)	1	0	15	yes	D
21. M, 79	2	IIB (T3)	3	0	15	no	D
22. M, 67	15	IVA (T3)	2	0	25	yes	A
23. M, 90	5	IIB (T3)	3	2	15	no	D
24. M, 85	4	IVA (T3)	3	0	4	yes	D
25. M, 31	8	IVA (T3)	3	1	71	yes	A
26. F, 81	2	IIB (T3)	3	1	18	no	A
27. F, 68	4	IB (T2)	2	0	35	no	A
28. M, 75	1	IIB (T3)	2	0	12	yes	D
29. M, 67	1	IVA (T3)	3	0	10	yes	A
30. M, 56	1	IIB (T3)	1	0	18	no	A
31. F, 72	7	IVA (T3)	2	0	12	yes	D
32. F, 81	2	IVA (T2)	2	0	3	yes	D
33. M, 69	11	IVA (T3)	3	0	8	yes	D
34. M, 80	16	IIB (T3)	3	0	5	no	D
35. M, 45	4	IIB (T3)	2	0	36	yes	D
36. F, 43	3	IIB (T3)	3	0	96	no	A
37. F, 75	32	IIB (T3)	3	2	144	no	A
38. F, 82	11	IIB (T3)	2	1	60	no	D
39. F, 72	10	IIB (T3)	2	2	38	no	D
40. M, 43	0	III (T3)	2	0	22	yes	D
41. M, 71	0	IIB (T3)	2	0	36	no	A
42. M, 50	0	IVA (T3)	1	0	4	no	D
43. M, 37	0	IVA (T3)	2	1	16	no	A
44. F, 75	15	IIB (T3)	1	0	1	no	D
45. M, 62	10	IIB (T3)	2	2	3	no	A

M, male; F, female.

1 indicates 25%-49%; 2, 50%-79%; 3, ≥80%.

0 indicates negative expression; 1, less than 75% of positive cells; 2, at least 75% of positive cells.

A, alive; D, dead; L, lost to follow-up.